Switzerland Innovation & Finance — April 18, 2026
Switzerland's Crypto Valley has cemented its position as Europe's dominant blockchain hub, capturing 47% of all European blockchain venture capital in 2025 with $728 million raised across 31 deals — a 37% year-on-year increase. The top 50 Swiss-based blockchain firms now carry a combined valuation of $467 billion, including 10 unicorns. On the pharma front, recent data points to continued global dominance by Swiss giants Roche and Novartis, even as domestic pressures mount.
Switzerland Innovation & Finance — April 18, 2026
Key Highlights
🔗 Crypto Valley Dominates European Blockchain VC
Switzerland's Crypto Valley — centered on the Zug–Zürich corridor — raised $728 million across 31 deals in 2025, accounting for 47% of all European blockchain venture capital, according to the annual CV VC Top 50 Report released this week. That marks a 37% year-on-year increase in funding.
Key data points from the report:
- 10 blockchain unicorns are now based in Switzerland, comprising 2 private companies and 8 blockchain platforms with publicly traded tokens
- The combined valuation of the top 50 Swiss-based firms stands at an estimated $467 billion
- Zug is home to approximately 41% of firms in the ecosystem, with over 1,766 blockchain and fintech companies registered nationally
- TON led individual deals in 2025
"Switzerland has definitively cemented its position as the central nervous system of Europe's cryptocurrency and blockchain industry." —
The report was released Wednesday by venture firm CV VC and widely covered across crypto and fintech media this week.
💊 Swiss Pharma: Global Strength, Local Scrutiny
Roche's 2025 full-year sales rose 7% at constant exchange rates to CHF 61.5 billion (~$79.8 billion), driven by strong demand for drugs targeting multiple sclerosis, eye diseases, and Haemophilia A. The company has 10 new molecules entering late-stage clinical trials.
Meanwhile, Novartis struck a $2 billion deal to acquire Excellergy, a Palo Alto-based allergy biotech that emerged only five months ago with $70 million in seed funding. Excellergy's lead asset, Exl-111, is an IgE antibody currently in Phase 1 development and is seen as a potential successor to blockbuster allergy drug Xolair.
Analysis
Switzerland's Crypto Valley: Structural Strength, Not a Trend
This week's CV VC report underscores that Switzerland's blockchain leadership is not incidental — it reflects deliberate policy, favorable tax treatment, crypto-friendly banking, and decades of fintech infrastructure. The Zug-Zürich corridor has built an ecosystem where over 1,766 firms now operate, with Zug hosting 41% of them.
The 37% jump in VC funding from 2024 to 2025, reaching $728 million, signals that institutional and global capital continues to flow preferentially into Switzerland over other European jurisdictions. The TON-led deals further suggest that major Layer-1 blockchain protocols view Swiss incorporation as strategically advantageous.
With 10 unicorns and a $467 billion aggregate valuation for the top 50 firms alone, Crypto Valley has transcended "startup hub" status — it is now a systemic node in the global digital asset economy. The Swiss regulatory framework (FINMA's pragmatic approach to token classification) and the country's political neutrality continue to attract projects seeking long-term legal certainty.
What to Watch
-
CV VC Top 50 ecosystem developments: As the annual report circulates, expect increased LP interest and potential new fund announcements targeting Swiss blockchain projects through mid-2026.
-
Novartis pipeline watch: The Excellergy acquisition signals Novartis is actively rebuilding its immunology pipeline ahead of Xolair patent pressures. Phase 1 data for Exl-111 will be a key milestone to track.
-
Roche late-stage trials: With 10 molecules entering late-stage clinical trials, Roche's pipeline readouts over the coming quarters will be closely watched by investors and analysts.
-
Swiss Fintech Week 2026: The annual gathering of Switzerland's fintech ecosystem brings together startups, investors, and incumbents for seven days of programming, including sessions on institutional digital asset strategies, real-world asset tokenization, stablecoins, CBDCs, and AI in blockchain scaling.
All factual claims are sourced from research results dated after April 11, 2026. Pharma figures for Roche refer to full-year 2025 results; the Novartis deal was reported approximately 3 weeks ago and falls within the coverage window.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
